公开(公告)号：EP0111560A4

公开(公告)日：1987-02-03

申请号：EP83902361

申请日：1983-06-14

申请人： KEY PHARMA

发明人： CHARLES HSIAO

IPC分类号： A61K9/22 ,  A61K9/50 ,  A61K9/62 ,  A61K31/60 ,  A61K9/36

CPC分类号： A61K31/60 ,  A61K9/5047

摘要： A sustained release aspirin dosage form permits the continuous delivery of aspiring into the gastrointestinal tract for a period of at least eight hours. The sustained release aspirin dosage form comprises a plurality of polymerically coated aspirin crystals each of which comprises an aspirin seed. The majority of aspirin seeds have a mesh size of from about 30 to about 60 mesh. Each of the aspirin seeds is individually coated with a polymeric mixture, which comprises from about 1.5 to about 15 parts by weight ethylcellulose and about one part by weight hydroxypropylcellulose.

公开(公告)号：EP0113373A4

公开(公告)日：1986-07-24

申请号：EP83902590

申请日：1983-07-08

申请人： KEY PHARMA

发明人： HSIAO CHARLES

IPC分类号： A61K9/50 ,  A61K9/52 ,  A61K31/49 ,  A61K9/62

CPC分类号： A61K9/5078 ,  A61K31/49

摘要： A sustained release quinidine dosage form comprising a plurality of pellets of an average diameter not greater than about 1 mm. Each pellet comprises a coating of quinidine over a nonpareil seed which is then coated with a mixture of about 3 to about 9 parts by weight ethylcellulose to about 1 part by weight hydroxypropylcellulose. The sum of such pellets in a container constitutes a single sustained release dosage unit of quinidine.

公开(公告)号：EP0112390A4

公开(公告)日：1986-07-23

申请号：EP83902383

申请日：1983-06-24

申请人： KEY PHARMA

发明人： HSIAO CHARLES

IPC分类号： A61K9/20 ,  A61K31/135 ,  A61K9/24

CPC分类号： A61K31/135 ,  A61K9/2054

公开(公告)号：EP0096074A4

公开(公告)日：1984-05-29

申请号：EP83900393

申请日：1982-12-20

申请人： KEY PHARMA

发明人： KEITH ALEC

IPC分类号： A61K31/04 ,  A61K9/00 ,  A61K9/22 ,  A61K9/28 ,  A61K31/13 ,  A61K31/49 ,  A61K9/32

CPC分类号： A61K9/2853 ,  A61K9/0004 ,  A61K9/284

摘要： An expandable lattice structure is a film of polyvinyl alcohol and polyethylene glycol having sufficient thickness to retain its structural integrity upon the application of an osmotic pressure and sufficient thinness whereby said expandable lattice structure is capable of sufficient expansion of its lattice structure under the influence of osmotic pressure whereby drug molecules are permitted to pass therethrough.

公开(公告)号：EP0144341A4

公开(公告)日：1985-07-30

申请号：EP84901536

申请日：1984-03-21

申请人： KEY PHARMA

发明人： BODOR NICHOLAS S

IPC分类号： C07D513/00 ,  C07D489/00 ,  C07D489/08 ,  C07D513/20 ,  A61K31/485 ,  C07D513/10

CPC分类号： C07D489/00 ,  C07D489/08

公开(公告)号：EP0083373A4

公开(公告)日：1985-02-28

申请号：EP82902562

申请日：1982-07-12

申请人： KEY PHARMA

发明人： KEITH ALEC DELL

IPC分类号： A61K31/46 ,  C07D451/00

CPC分类号： A61K31/46

摘要： A method of providing a person subject to a sudden turbulent motion protection from motion sickness which comprises spraying into the nasal passages of said person a sufficient amount of scopolamine whereby said person is protected from said motion sickness upon the entry of said scopolamine into the bloodstream of said patient.

公开(公告)号：EP0108145A4

公开(公告)日：1984-09-28

申请号：EP83902042

申请日：1983-05-12

申请人： KEY PHARMA

发明人： SACKNER MARVIN A KEY PHARMACEU ,  WATSON HERMAN KEY PHARMACEUTIC

IPC分类号： A61M15/00 ,  A61M16/00

CPC分类号： A61K9/0073 ,  A61M15/0086 ,  A61M15/0088 ,  A61M15/009 ,  A61M2205/42

摘要： A method and an apparatus for administering a metered dose of a drug through an oronasal passage for absorption on the mucous tissue without entry of the drug into the gastrointestinal tract of a patient includes introducing an aerosol of the drug into an expanded bag (50) and means (56 and 19) for communicating the drug with the oronasal passage of the patient, which bag otherwise is substantially impervious to the passage of air, collapsing the expanded bag while the means for communication with the oronasal passageway is in position to deliver the drug into the oronasal passage of the patient. The airbag provided has end caps (51 and 52), joined with a collapsible material (53), one of the end caps having an aperture (57) connected to the communicating means.

公开(公告)号：EP0083371A4

公开(公告)日：1983-12-19

申请号：EP82902506

申请日：1982-07-08

申请人： KEY PHARMA

发明人： KEITH ALEC DELL ,  SNIPES WALLACE

IPC分类号： A61K31/12 ,  A61K9/00 ,  A61K9/14 ,  A61K9/70 ,  A61K31/21 ,  A61L15/00 ,  A61L15/03

CPC分类号： A61K9/7084 ,  A61K9/006 ,  A61K9/146 ,  A61K31/21

摘要： A trinitroglycerol containing substantially disaccharide-free polymeric diffusion matrix for the transdermal systemic delivery of trinitroglycerol through the skin of a patient. The polymeric diffusion matrix contains sufficient trinitroglycerol to be released over a prolonged period of time and comprises a first lower molecular weight, partial hydrolyzed polyvinylalcohol component, a second higher molecular weight, essentially fully hydrolyzed polyvinylalcohol component, and glycerol.

公开(公告)号：EP0178299A4

公开(公告)日：1987-04-28

申请号：EP84901535

申请日：1984-03-21

申请人： KEY PHARMA

发明人： HSIAO CHARLES H

IPC分类号： A61K9/20 ,  A61K9/22 ,  A61K31/19 ,  A61K9/26 ,  A61K9/52 ,  A61K31/78

CPC分类号： A61K9/2027 ,  A61K9/2054 ,  A61K31/19

公开(公告)号：EP0083372A4

公开(公告)日：1985-02-28

申请号：EP82902507

申请日：1982-07-08

申请人： KEY PHARMA

发明人： HSIAO CHIIN HSIUNG

IPC分类号： A61K9/00 ,  A61K9/50 ,  A61K9/52 ,  A61K9/58 ,  A61K9/62 ,  A61K31/52

CPC分类号： A61K31/52 ,  A61K9/5078

摘要： Theophylline is provided in a sustained release formulation which comprises a plurality of micropellets of theophylline which is coated over a seed in a first coat with polyvinylpyrrolidone and a second coat of cellulose derivatives. The sustained release theophylline form is sprinkled into the normal food of a patient, particularly a child or elderly patient.